<DOC>
	<DOCNO>NCT01593072</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability healthy male female subject intravenous ( IV ) infusion AVI 7537 compare match placebo evaluate pharmacokinetics ( PK ) .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability Pharmacokinetics AVI-7537 Healthy Adult Volunteers</brief_title>
	<detailed_description>The purpose study evaluate safety tolerability 14 daily intravenous ( IV ) infusion ascend dos AVI 7537 compare match placebo healthy male female subject . To evaluate pharmacokinetics ( PK ) 14 daily dos AVI-7537 healthy male female subject</detailed_description>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Hemorrhagic Fever , Ebola</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>A subject must meet follow criterion eligible study . 1 . Man woman 18 50 year age , inclusive , time screen . 2 . Body mass index 18 kg/m2 35 kg/m2 , inclusive , time screen Checkin ( Day 1 ) . 3 . Good general health ( chronic health condition ) determine Investigator . 4 . Female subject must nonchildbearing potential ( e.g. , confirm postmenopausal undergone surgical sterilization ) must , conjunction sexual partner ( ) , use 2 form medically acceptable contraception ( e.g. , oral contraception conjunction male condom ) screen period entire duration study include 28day post last dose followup . 5 . Male subject must either sterile agree use , entire duration study include 28 day post last dose followup , male condom female sexual partner must also use medically acceptable form birth control ( e.g . oral contraceptive ) . 6 . Male subject must agree donate sperm least 30 day last infusion study medication . 7 . Able understand requirement study , provide write informed consent ( evidenced signature inform consent document approve Institutional Review Board [ IRB ] ) , agreeable abide study restriction . A subject meet follow criterion exclude study . 1 . Pregnancy breastfeed . 2 . A positive urine blood screen drug abuse , include alcohol . 3 . Use tobacco nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch , nicotine lozenge , nicotine gum ) within 6 month prior Checkin ( Day 1 ) . 4 . A positive cotinine test indicate recent nicotine use . 5 . Donated blood within 90 day plasma within 30 day first dose Day 1 . 6 . Active substance abuse medical psychiatric condition could jeopardize subject 's safety subject 's ability comply protocol . 7 . Use medication apart vitamin , acetaminophen , hormonal contraception within 14 day first dose Day 1 . Subjects mild seasonal allergy may use antihistamine discretion Investigator approval Sponsor Medical Monitor . 8 . Participation interventional clinical trial within 45 day first dose Day 1 ( i.e. , receive investigational drug ) . 9 . Recipient organ transplant ( solid hematopoietic ) . 10 . Prolonged QTcF interval &gt; 440 m male &gt; 460 m female use average triplicate electrocardiogram ( ECGs ) collect screening , Day 1 , prior dose Day 1 . 11 . Other clinically significant ECG abnormality , determine Investigator . 12 . Any clinically significant abnormal hematology , chemistry , coagulation , urinalysis value , determine Investigator . 13 . Glomerular filtration rate ( GFR ) &lt; 80 mL/min , base Modification Diet Renal Disease equation . 14 . Urinealbumintocreatinine ratio ( UACR ) &gt; 30 mg/g . 15 . Positive test human immunodeficiency virus ( HIV1 serology ) know HIV infection . 16 . Positive result hepatitis B surface antigen ( HBsAg ) hepatitis C virus ( HCV ) antibody . 17 . Use alcoholcontaining food beverage within 72 hour prior Checkin Day 1 . 18 . Use caffeinecontaining food beverage within 24 hour prior Checkin Day 1 . 19 . Febrile illness significant infection within 48 hour administration first dose study drug Day 1 . Note : Inclusion subject review member AVI BioPharma Clinical Personnel prior enrollment trial . Written approval member AVI BioPharma Clinical Personnel require prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Multiple Ascending Dose ( MAD )</keyword>
	<keyword>Ebola Virus</keyword>
	<keyword>Post Exposure Prophylaxis</keyword>
	<keyword>EHF</keyword>
</DOC>